BioSpace News Archive

POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, announced data will be released at ESMO Congress 2022 in Paris, France about the efficacy and safety of PNT2002 in the lead-in cohort of the SPLASH trial.

CatalYm announced that the mature results from its Phase 1, first-in-human trial “GDFATHER-1” will be presented in an oral presentation at the European Society for Medical Oncology Congress 2022.

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause.